An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling
Science Advances · 2026
DOI: 10.1126/sciadv.aeb7558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Irena Selicharová und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 16000 Praha 6, Czech Republic. Hauptthemen laut MEDLINE: Insulin, Receptor, IGF Type 1, Signal Transduction, Protein Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Czech Science Foundation, Institute of Organic Chemistry and Biochemistry.
Abstract (Originalsprache)
Insulin and insulin-like growth factors (IGF-1 and IGF-2) regulate metabolism, growth, and development via related receptors. In contexts such as brain function or fetal development, coordinated signaling by all three hormones is essential. We report the engineering of [GluB10, D-HisB24, GlyB31, TyrB32]-insulin ( 1 Ins ), an analog with high affinity for IR-A, IR-B, and especially IGF-1R. 1 Ins binds IGF-1R ~1000-fold more strongly than native insulin, approaching IGF-1 levels. Cryo–electron microscopy structures reveal how minimal substitutions in 1 Ins enable effective binding to both IR-A and IGF-1R. In neuronal cells, 1 Ins robustly activates both IR and IGF-1R pathways, promotes survival, and exceeds native ligands in neuroprotective assays. In vivo, 1 Ins regulates glucose effectively in mice and rats. Phosphoproteomic profiling confirms dual pathway activation and identifies targets specific to 1 Ins . These findings demonstrate that rational design of dual-receptor agonists can yield potent, versatile ligands with therapeutic promise in metabolic control, neuroprotection, and regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 16000 Praha 6, Czech Republic.
- WEHI, 1G Royal Parade, Parkville, Victoria 3052, Australia.
- Department of Medical Biology, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Parkville, Victoria, 3010, Australia.
- Department of Genetics and Microbiology, Faculty of Science, Charles University, 12840 Prague 2, Czech Republic.
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
ORCID-Profile: Irena Selicharová, Nicholas S Kirk, Anna Kertisová, Marta Lubos, Terezie Ticháčková, Lenka Žáková, Jana Březinová, Jan Voldřich, Miroslav Hájek, Jiří Jiráček
Förderung
- NIA NIH HHS
- Czech Science Foundation
- Institute of Organic Chemistry and Biochemistry
- Einstein Nathan Shock Center Health Span Interventions Core
Zitieren
APA
Selicharová, I., Kirk, N. S., Kertisová, A., Lubos, M., Mitrová, K., Ticháčková, T., Žáková, L., Chrudinová, M., Březinová, J., Harant, K., Voldřich, J., Hájek, M., Huffman, D. M., & Jiráček, J. (2026). An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling. Science Advances. https://doi.org/10.1126/sciadv.aeb7558
Vancouver
Selicharová I, Kirk NS, Kertisová A, Lubos M, Mitrová K, Ticháčková T, et al. An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling. Science Advances. 2026. doi:10.1126/sciadv.aeb7558
BibTeX
@article{Selicharov2026,
author = {Selicharová, Irena and Kirk, Nicholas S and Kertisová, Anna and Lubos, Marta and Mitrová, Katarína and Ticháčková, Terezie and Žáková, Lenka and Chrudinová, Martina and Březinová, Jana and Harant, Karel and Voldřich, Jan and Hájek, Miroslav and Huffman, Derek M and Jiráček, Jiří},
title = {An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeb7558}
}
EUVIMED